Form 4: LivaNova Director Reports Routine Share Transactions and New Equity Grant

LivaNova PLC Director Barry James Christopher reported the vesting of 3,416 restricted stock units, the sale of 410 shares for tax purposes, and the grant of 4,042 new restricted stock units.

Summary

• Director Barry James Christopher acquired 3,416 ordinary shares of LivaNova PLC on June 15, 2025, through the vesting of previously granted restricted stock units (RSUs) under the 2015 Incentive Award Plan.
• Concurrently, 410 ordinary shares were disposed of at a price of $45.76 per share to satisfy tax liabilities related to the RSU vesting.
• Following these transactions, Mr. Christopher's direct beneficial ownership of ordinary shares decreased from 4,772 to 4,362.
• Additionally, Mr. Christopher was granted 4,042 new restricted stock units under the Company's 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2026, contingent on continued service.

Sentiment

Score: 7

Explanation: The filing indicates routine compensation events for a director, including RSU vesting and a new grant, which are generally positive for aligning management interests with shareholders. The share sale is for tax purposes, which is standard and not indicative of negative sentiment.

Positives

• Vesting of 3,416 restricted stock units indicates successful achievement of prior performance or service conditions.
• Grant of 4,042 new restricted stock units demonstrates continued commitment of the director to the company and aligns his interests with shareholders.
• The new RSU grant under the 2025 Director Incentive Award Plan suggests ongoing incentive programs for directors.

Negatives

• 410 ordinary shares were sold to cover tax liabilities, which represents a reduction in direct share ownership.

Future Outlook

The grant of new Restricted Stock Units vesting in June 2026 indicates a forward-looking incentive structure for directors, contingent on their continued service to the company.

Industry Context

This Form 4 filing reflects routine insider transactions related to executive compensation, specifically the vesting of equity awards and subsequent tax-related share sales, which are common practices across publicly traded companies in various industries, including medical technology.

Comparison to Industry Standards

• The transactions, including RSU vesting and tax-related share sales, are standard practices for executive compensation in publicly traded companies.
• The grant of new RSUs aligns with common industry practices to incentivize long-term commitment and performance from directors.
• No specific comparable companies or projects are mentioned in this filing to allow for a detailed comparative assessment.

Corporate Governance

Stakeholder Impact

• Shareholders: The vesting of RSUs and new grants align director interests with shareholders, potentially fostering long-term value creation. The tax-related share sale is a minor, routine event.
• Employees: No direct impact on general employees is indicated by this filing.
• Management/Directors: The transactions directly impact Director Barry James Christopher's compensation and equity holdings, reinforcing his commitment to the company.

Next Steps

• The 4,042 new Restricted Stock Units granted to Director Barry James Christopher are scheduled to vest on June 15, 2026, subject to his continued service to LivaNova PLC.

Key Dates

Recommendation

Keywords

LivaNova PLC, LIVN, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Share Disposal, Director Compensation, Equity Grant, Corporate Governance